Article Sidebar

PDF (Tiếng Việt)
Published: 2024-07-31
Abstract Views: 126
Views PDF (Tiếng Việt): 82
DOI: https://doi.org/10.52852/tcncyh.v179i6.2441
Issue
Vol. 179 No. 6 (2024)
Section
Các bài báo
How to Cite
Anh, N. T. H., Điển, T. M., Vân, Đặng T. H., & Nhật, N. H. (2024). 2. Medium-term progress of pulmonary hypertension in bronchopulmonary dysplasia. Journal of Medical Research, 179(6), 10-18. https://doi.org/10.52852/tcncyh.v179i6.2441

2. Medium-term progress of pulmonary hypertension in bronchopulmonary dysplasia

Nguyen Thi Hai Anh, Tran Minh Dien, Dang Thi Hai Van, Nguyen Huu Nhat

Main Article Content

Abstract

Pulmonary hypertension (PH) is a common cardiovascular complication in bronchopulmonary dysplasia (BPD), with deterioration in the neonatal period  leading to subsequent hospitalizations. The study aimed to evaluate the progression of pulmonary hypertension in infants with bronchopulmonary dysplasia in the first 12 months of life. This was a case series conducted at the Vietnam National Children's Hospital from January 2022 to April 2024. 44 patients with PH - BPD were enrolled in the study, and the 12-month mortality rate was 40.91%; 6-month mortality was 34,09%. All  deceased patients still had PH with  a higher rate of mechanical ventilation up to 28 days of life, more severe BPD, severe PH, pneumonia, and HFO mechanical ventilation than the surviving patients. The rate of treatment with Sildenafil was 52.27%, the combination of Sildenafil and Bosentan was 13.64%, and the combination of Sildenafil and Iloprost was 13.64%. The rate of recovery from PH at 3 months, 6 months, and 12 months was 15.91%; 44.19%; 52.50%; respectively. PH-BPD has a high mortality rate in the first 6 months, but patients who survive have a high chance of completely recovering from PH in the first 12 months of life.

Article Details

Keywords

Pulmonary hypertension, bronchopulmonary dysplasia, preterm

References

1. Kwon HW, Kim HS, An HS, et al. Long-Term Outcomes of Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia. Neonatology. 2016; 110(3): 181-189. doi:10.1159/000445476.
2. Weismann CG, Asnes JD, Bazzy-Asaad A, Tolomeo C, Ehrenkranz RA, Bizzarro MJ. Pulmonary hypertension in preterm infants: results of a prospective screening program. J Perinatol. 2017; 37(5): 572-577. doi:10.1038/jp.2016.255.
3. Lagatta JM, Hysinger EB, Zaniletti I, et al. The Impact of Pulmonary Hypertension in Preterm Infants with Severe BPD Through One Year. J Pediatr. 2018; 203: 218-224.e3. doi:10.1016/j.jpeds.2018.07.035.
4. Carlton EF, Sontag MK, Younoszai A, et al. Reliability of Echocardiographic Indicators of Pulmonary Vascular Disease in Preterm Infants at Risk for Bronchopulmonary Dysplasia. J Pediatr. 2017; 186: 29-33. doi:10.1016/j.jpeds.2017.03.027.
5. Mourani PM, Sontag MK, Younoszai A, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015; 191(1): 87-95. doi:10.1164/rccm.201409-1594OC.
6. Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021; 89(3): 446-455. doi:10.1038/s41390-020-0993-4.
7. Lachica CI, Begley A, Magee J, Manimtim W. Outcomes of Infants treated for BPD associated pulmonary hypertension and home mechanical ventilation. Pediatrics. 2018; 142 (1 MeetingAbstract): 187-187. doi:10.1542/peds.142.1_MeetingAbstract.187.
8. Du Y, Yuan L, Zhou JG, et al. Echocardiography evaluation of bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective observational cohort study. Transl Pediatr. 2021; 10(1): 73-82. doi:10.21037/tp-20-192.
9. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era. Pediatrics. 2007; 120(6): 1260-1269. doi:10.1542/peds.2007-0971.
10. Arjaans S, Haarman MG, Roofthooft MTR, et al. Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age. Archives of Disease in Childhood - Fetal and Neonatal Edition. 2021; 106(1): 45-50. doi:10.1136/archdischild-2019-318531.
11. Jobe AH, Bancalari E. Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2001; 163(7): 1723-1729. doi:10.1164/ajrccm.163.7.2011060.
12. Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. J Pediatr. 2017; 188:24-34.e1. doi:10.1016/j.jpeds.2017.05.029.
13. del Cerro MJ, Sabaté Rotés A, Cartón A, et al. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr Pulmonol. 2014; 49(1): 49-59. doi:10.1002/ppul.22797.
14. Altit G, Bhombal S, Hopper RK, Tacy TA, Feinstein J. Death or resolution: the “natural history” of pulmonary hypertension in bronchopulmonary dysplasia. J Perinatol. 2019; 39(3): 415-425. doi:10.1038/s41372-018-0303-8.
15. Du Y, Yuan L, Zhou JG, et al. Echocardiography evaluation of bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective observational cohort study. Transl Pediatr. 2021; 10(1): 73-82. doi: 10.21037/tp-20-192.
16. Cohen JL, Nees SN, Valencia GA, Rosenzweig EB, Krishnan US. Sildenafil Use in Children with Pulmonary Hypertension. J Pediatr. 2019; 205: 29-34.e1. doi:10.1016/j.jpeds.2018.09.067.